Live Activities by Credit Type
-
Advances in Biomarker-Driven Immune Checkpoint Blockade for Selected Types of Solid Tumors
·
Various Cities, Around
·
, 0, US
·
August
30
, 2017 -
Apr
27,
2018
-
Cancer Immunotherapy: An Interprofessional Approach to the Management of Immune-Mediated Adverse Events
·
Various Cities, Around
·
, 0, US
·
August
30
, 2017 -
Apr
27,
2018
-
Applying Clinical Trial Data and Guideline Recommendations to Individualize Duration of Dual Antiplatelet Therapy
·
Various Cities
·
, 0
·
November
15
, 2017 -
Jun
20,
2018
-
Paving The Path To Precision Medicine in NSCLC: Using Biomarkers to Determine Treatment Course
·
Various Cities, Around
·
, 0, US
·
February
2
-
Oct
26,
2018
-
Revolutionizing the Paradigm and Prognosis of B-Cell Malignancies with BTK Inhibitors
·
Various Cities, Around
·
, 0, US
·
February
26
-
Dec
21,
2018
-
Advances in Biomarker-Driven Immune Checkpoint Blockade for Selected Types of Solid Tumors
·
TBA
·
Salisbury, MD, US
·
April
27,
2018
-
Applying Clinical Trial Data and Guideline Recommendations to Individualize Duration of Dual Antiplatelet Therapy
·
TBA
·
New Brunswick, NJ
·
April
27,
2018
-
Applying Clinical Trial Data and Guideline Recommendations to Individualize Duration of Dual Antiplatelet Therapy
·
TBA
·
Joplin, MO
·
April
30,
2018
-
Paving The Path To Precision Medicine in NSCLC: Using Biomarkers to Determine Treatment Course
·
TBA
·
Bristol, PA
·
May
9,
2018
-
Medicine Grand Rounds: Examining Effective Strategies in Oral Anticoagulation Reversal
·
TBA
·
Philadelphia, PA
·
May
9,
2018
-
Applying Clinical Trial Data and Guideline Recommendations to Individualize Duration of Dual Antiplatelet Therapy
·
TBA
·
Hilo, HI
·
May
11,
2018
-
Cancer Immunotherapy: An Interprofessional Approach to the Management of Immune-Mediated Adverse Events
·
TBA
·
Billings, MT, US
·
May
15,
2018
-
Advances in Biomarker-Driven Immune Checkpoint Blockade for Selected Types of Solid Tumors
·
TBA
·
Bristol, PA, US
·
May
16,
2018
-
Revolutionizing the Paradigm and Prognosis of B-Cell Malignancies with BTK Inhibitors
·
TBA
·
Baltimore, MD
·
May
17,
2018
-
Advances in Biomarker-Driven Immune Checkpoint Blockade for Selected Types of Solid Tumors
·
TBA
·
Daytona Beach, FL, US
·
May
23,
2018
-
Advances in Biomarker-Driven Immune Checkpoint Blockade for Selected Types of Solid Tumors
·
TBA
·
Palm Coast, FL, US
·
May
23,
2018
-
Applying Clinical Trial Data and Guideline Recommendations to Individualize Duration of Dual Antiplatelet Therapy
·
TBA
·
Brooklyn, NY
·
May
29,
2018
-
Advances in Biomarker-Driven Immune Checkpoint Blockade for Selected Types of Solid Tumors
·
TBA
·
Oxnard, CA, US
·
May
30,
2018
-
Applying Clinical Trial Data and Guideline Recommendations to Individualize Duration of Dual Antiplatelet Therapy
·
TBA
·
Corinth, MS
·
June
19,
2018
-
Applying Clinical Trial Data and Guideline Recommendations to Individualize Duration of Dual Antiplatelet Therapy
·
TBA
·
Lawrenceburg, TN
·
June
21,
2018
-
Paving the Path to Precision Medicine in NSCLC: Using Biomarkers to Determine Treatment Course
·
JW Marriott Marquis Miami
·
Miami, FL
·
July
14,
2018
-
Revolutionizing the Paradigm and Prognosis of B-Cell Malignancies with BTK Inhibitors
·
TBA
·
Stockton, CA
·
July
17,
2018
-
Paving The Path To Precision Medicine in NSCLC: Using Biomarkers to Determine Treatment Course
·
TBA
·
Titusville, FL
·
August
10,
2018
-
Revolutionizing the Paradigm and Prognosis of B-Cell Malignancies with BTK Inhibitors
·
TBA
·
New Hyde Park, NY
·
September
19,
2018
Online Activities by Credit Type
|
Lung cancer is the most common cancer worldwide, as well as the leading cause of cancer death.1 Non small-cell lung cancer (NSCLC) accounts for more than 85% of lung cancer cases, and is...
Faculty
|
Activity Details
- Credit Amounts:
-
Type: Video Webcast
- Expires: Jun 19, 2018
- Cost: Free
|
|
Oral anticoagulants are used for a variety of conditions such as atrial fibrillation, mechanical heart valves, and the prevention and treatment of venous thromboembolism. Although the risk/benefit ratio of...
Faculty
- Christian Ruff, MD, MPH
- Charles V. Pollack, Jr., M.A., M.D., FACEP, FAAEM, FAHA, FESC, FCPP
|
|
|
Activity Details
- Credit Amounts:
- CME: 1.00
- CPE: 1.00
- CNE: 1.00
- Other: 1.00
-
Type: PDF
- Expires: May 9, 2018
- Cost: Free
|
|
Faculty
|
Activity Details
- Credit Amounts:
-
Type: PDF
- Expires: Apr 22, 2018
- Cost: Free
|
|
E-mail
Begin